A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck
Robert I. Haddad(Dana-Farber Cancer Institute), Geoffrey I. Shapiro(Brigham and Women's Hospital)
Cited by 67
Related Papers
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|495
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma
|JAMA Oncology|2020|340
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
|Blood|2012|297
Frameshift events predict anti–PD-1/L1 response in head and neck cancer
|JCI Insight|2018|276